Patient
SITE005-0014
withdrawn Phase IIIA Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · SITE005 (FRA) (Dr. Muller)
consented 2025-09-07
Adverse events
8
Serious AEs
2
Open data queries
0
Luna dropout signal
—
not on Luna
Adverse events 8
Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-07-03 (study day 108); relationship: not assessed
Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-06-28 (study day 103); relationship: not assessed
Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-06-28 (study day 103); relationship: NOT RELATED
Grade 4 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-06-05 (study day 80); relationship: not assessed; serious criteria: life-threatening
Grade 4 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-05-28 (study day 72); relationship: NOT RELATED; serious criteria: life-threatening
Grade 1 Fatigue — outcome: RECOVERED/RESOLVED; onset 2022-05-11 (study day 55); relationship: NOT RELATED
Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-05-06 (study day 50); relationship: not assessed
Grade 1 Asthenia — outcome: RECOVERED/RESOLVED; onset 2022-05-05 (study day 49); relationship: not assessed
Data queries 0
No data queries
The CDM sweep raises queries on inconsistent fields.
Luna engagement
This participant doesn't use Luna
Invite them from the site to track mood, adherence and check-ins.